In fact, the HER-2-positive breast cancer subtype has an elevated risk for developing metastatic disease, and the trastuzumab treatment has improved the efficacy of chemotherapy and delayed the emergence of metastatic disease [33,34,35]. This evidence concerns the gene ERBB2 and breast carcinoma.